1. Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia
- Author
-
Seiji Yamaguchi, Mika Tadokoro, Takeshi Taketani, Seiji Mishima, Hajime Ogushi, Shunsuke Yuba, Rie Kanai, Mariko Abe, Yoshihiro Katsube, and Seiji Fukuda
- Subjects
Oncology ,medicine.medical_specialty ,Cyclophosphamide ,business.industry ,Mesenchymal stem cell ,Hypophosphatasia ,medicine.disease ,Fludarabine ,Transplantation ,Myelogenous ,Leukemia ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Internal medicine ,Pediatrics, Perinatology and Child Health ,Immunology ,medicine ,Bone marrow ,business ,medicine.drug - Abstract
Bone marrow (BM) transplantation (BMT) is one of the treatment strategies for congenital metabolic disease, but leukemia secondary to intensive cytoreductive treatment is a major concern. Besides BM cells, mesenchymal stem cells (MSC) are also used for transplantation. An 8-month-old girl with hypophosphatasia underwent transplantation of haploidentical BM cells followed by two transplants of MSC obtained from her father to facilitate osteogenesis. Fludarabine(Flu)/cyclophosphamide (CPA)/anti-thymocyte globulin were used for myeloablative conditioning, but the patient developed therapy-related leukemia harboring t(9;22)(q34;q11.2); minor BCR-ABL (t-leukemia with Ph) at the age of 32 months. At the age of 40 months she underwent a second BM and third MSC transplant from the same donor. Thereafter, she achieved complete histological and molecular remission. The present case suggests that the combination of cytotoxic agents (Flu/CPA) and MSC led to t-leukemia with Ph as a consequence of chromosome instability and suppression of host anti-tumor immunity.
- Published
- 2013